Discontinued operations and assets held for sale - Cash flows (Details) - Discontinued Operations [Member] - EUR (€) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Cash flows from discontinued operations | |||
| Net cash flow used in operating activities | € (851,000) | € (36,367,000) | € (175,627,000) |
| Net cash flow used in investing activities | 7,238,000 | (8,949,000) | (105,000) |
| Net cash flow used in financing activities | (1,928,000) | ||
| Net cash flow from discontinued operations related to Jyseleca (filgotinib) business. | € 6,387,000 | € (45,316,000) | € (177,660,000) |